Dianthus Therapeutics (DNTH) Restructuring Costs (2023)
Dianthus Therapeutics' (DNTH) quarterly Restructuring Costs came in at $1.9 million in Q2 2023, down 89.35% quarter-over-quarter from $18.0 million in Q1 2023.
Dianthus Therapeutics (DNTH) Restructuring Costs (2023) Analysis & Trends
Dianthus Therapeutics' Restructuring Costs history runs 1 years deep, the most recent figure standing at $1.9 million for Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Dianthus Therapeutics | 3.92 Bn | 3.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 18.00 Mn |